Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Mar;37(3):306-310.
doi: 10.1038/jp.2016.218. Epub 2016 Dec 1.

Treatment and follow-up of venous thrombosis in the neonatal intensive care unit: a retrospective study

J C Bohnhoff  1   2 , S A DiSilvio  3   2 , R K Aneja  1   2   4 , J R Shenk  5 , Y A Domnina  1   2   4 , B S Brozanski  1   3   2 , M Good  1   3   2
Affiliations

Treatment and follow-up of venous thrombosis in the neonatal intensive care unit: a retrospective study

J C Bohnhoff et al. J Perinatol. 2017 Mar.

Abstract

Objective: The critically ill, premature patients of neonatal intensive care units are susceptible to venous thrombosis, an adverse event associated with short- and long-term morbidity. Venous thrombosis is frequently treated with low-molecular-weight heparins (LMWHs) such as enoxaparin, but optimal dosing of LMWH must balance the morbidity of venous thrombosis with the potential adverse affects of anticoagulation. The optimal dosing of enoxaparin for premature infants is unclear. The objective of this study was to describe enoxaparin therapy and follow-up in critically ill neonates diagnosed with venous thrombosis.

Study design: Retrospective medical record review in the neonatal intensive care unit (NICU) in a single tertiary care institution. Infants with venous thrombosis diagnosed in the NICU were identified using preexisting quality improvement lists and medical records.

Results: Twenty-six infants with 30 venous thromboses were identified with a median gestational age of 31 weeks at birth. Eighteen (69%) infants received enoxaparin for venous thrombosis during their hospitalization, beginning with a median dose of 1.5 mg kg-1 every 12 h. This dose was increased to a median of 2.1 mg kg-1 every 12 h to achieve target anti-factor Xa levels. The target dose was significantly higher in patients with a postmenstrual age of <37 weeks. Enoxaparin treatment was documented after discharge in 12 patients, continuing for a median of 99 days. Four patients died during hospitalization and their deaths were not attributable to venous thrombosis or anticoagulation complication. Follow-up documentation between 6 and 24 months after venous thrombosis diagnosis revealed no major morbidity of venous thrombosis or enoxaparin therapy.

Conclusion: Our data reinforce the relative safety and necessity of enoxaparin doses above 1.5 mg kg-1 per 12 h in most neonates. This was particularly true for infants at lower postmenstrual age.

PubMed Disclaimer

Conflict of interest statement

Disclosures: The authors have nothing to disclose and no conflicts of interest.

Conflicts of Interest

None of the authors have any conflicts of interest or competing financial relationships in relation to the work described.

Figures

Figure 1
Figure 1. Clinical course and follow-up of patients with venous thromboses
Resolution refers to ultrasound-confirmed resolution of all venous thromboses in a given patient. VT=venous thrombosis.
See this image and copyright information in PMC

References

    1. Stein PD, Kayali F, Olson RE. Incidence of venous thromboembolism in infants and children: data from the National Hospital Discharge Survey. J Pediatr. 2004;145(4):563–565. - PubMed
    1. Chalmers EA. Epidemiology of venous thromboembolism in neonates and children. Thromb Res. 2006;118(1):3–12. - PubMed
    1. Higgerson RA, Lawson KA, Christie LM, Brown AM, McArthur JA, Totapally BR, et al. Incidence and risk factors associated with venous thrombotic events in pediatric intensive care unit patients. Pediatr Crit Care Med. 2011;12(6):628–634. - PubMed
    1. Amankwah EK, Atchison CM, Arlikar S, Ayala I, Barrett L, Branchford BR, et al. Risk factors for hospital-sssociated venous thromboembolism in the neonatal intensive care unit. Thromb Res. 2014;134(2):305–309. - PMC - PubMed
    1. Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen DM, et al. Development of the human coagulation system in the full-term infant. Blood. 1987;70(1):165–172. - PubMed

Publication types